Title: The Effect of Nafamostat Mesilate Infusion after ERCP for Post-ERCP Pancreatitis
Version: 1 Date: 02 Nov 2021
Reviewer's report:
Dear authors,
I find your paper interesting since you have focused on the high risk patients. It would be
interesting to see results of prospectice randomised control trial, since (as you have also noticed)
this is retrospective review of avaiable data with potentiel bias. Also, you have high incidence
of PEP (17.4%) probably because the focused group is high risk patient - maybe that would be
good to explain in paper.
Title: The Effect of Nafamostat Mesilate Infusion after ERCP for Post-ERCP Pancreatitis
Version: 1 Date: 02 Nov 2021
Reviewer's report:
Dear authors,
I find your paper interesting since you have focused on the high risk patients. It would be
interesting to see results of prospectice randomised control trial, since (as you have also noticed)
this is retrospective review of avaiable data with potentiel bias. Also, you have high incidence
of PEP (17.4%) probably because the focused group is high risk patient - maybe that would be
good to explain in paper.
Please review this paper.
user
Title: The Effect of Nafamostat Mesilate Infusion after ERCP for Post-ERCP Pancreatitis
Version: 1 Date: 02 Nov 2021
Reviewer's report:
Dear authors,
I find your paper interesting since you have focused on the high risk patients. It would be
interesting to see results of prospectice randomised control trial, since (as you have also noticed)
this is retrospective review of avaiable data with potentiel bias. Also, you have high incidence
of PEP (17.4%) probably because the focused group is high risk patient - maybe that would be
good to explain in paper.
assistant